CJC-1295: Evidence, Legal Status, and Safety
CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analog with no completed human trials establishing safety or efficacy for its popular longevity, muscle-gain, or fat-loss uses. It is not FDA-approved, reportedly on the FDA's restricted-compounding list pending formal review, and banned at all times under WADA's anti-doping code. Andrew Huberman has publicly cited a clinical-trial death linked to cardiovascular dysfunction in this drug class.
Understand the mechanism A synthetic growth-hormone-releasing hormone (GHRH) analog, the same mechanism family as tesamorelin, engineered for a longer half-life so it stimulates more sustained growth-hormone release.
The longer half-life is the main engineering difference from tesamorelin, not a difference in evidence quality.
See what the human evidence actually is No completed human RCTs establishing safety or efficacy for CJC-1295's popular uses were found. It is not an FDA-reviewed drug.
The absence of trial data is the headline fact, not a technicality.
Know where it actually stands Not FDA-approved for any use. Reported on the FDA's 503A Category 2 restricted-compounding list as of April 2026, one of five peptides in a formal FDA review process. Banned at all times under WADA's S2 category.
“Under formal review” is not the same as “approved” or “newly legal,” despite how it's often marketed.
Know the real risk GH-secretagogue class effects, water retention, joint or soft-tissue swelling, potential insulin resistance, and a theoretical concern about stimulating GH-sensitive tissue growth, are described for the class generally. CJC-1295-specific human safety data is not established. Andrew Huberman has publicly cited a clinical-trial death linked to cardiovascular dysfunction associated with this compound class.
A cited clinical-trial death is a real safety signal, not gray-market rumor, and belongs on this page plainly.
No completed human randomized controlled trials establishing safety or efficacy for CJC-1295's popular longevity, muscle-gain, or fat-loss uses were found; it is not an FDA-reviewed drug.
View sources
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (CJC-1295 segment, cites a clinical-trial death)
Peter Attia, AMA #83: Peptides, evaluating the science, safety, and hype (CJC-1295 named in his evidence buckets)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering CJC-1295 who wants the honest evidence before discussing it with a clinician
- Athletes checking WADA and anti-doping status
- Readers comparing CJC-1295 to FDA-approved GH-axis drugs like tesamorelin
- Readers who want to know what credible physicians actually say about it
Cautions
- Not FDA-approved for any use; reported on the FDA's restricted-compounding list pending formal review.
- Banned at all times under WADA's anti-doping code (S2); can result in a competition ban if detected.
- No completed human RCT establishes its safety or efficacy for the popular use case; a clinical-trial death linked to cardiovascular dysfunction has been publicly cited for this compound class.
- Educational only, not medical advice.